In May 2016, Grupo Ferrer announced that it would acquire inhaled drug company Alexza Pharmaceuticals; as of June 21, 2016, the company says, Ferrer Pharma has merged into Alexza Pharmaceuticals, with Alexza now a wholly owned subsidiary of Ferrer.
Ferrer already marketed Alexza’s Staccato inhaled loxapine in much of the world and had become Alexza’s largest shareholder in 2014. Alexza’s pipeline includes inhaled alprazolam for the treatment of acute repetitive seizures in epilepsy patients and inhaled zaleplon for the treatment of insomnia.
Read the Alexza and Ferrer press release.
